Improved NYVAC-based vaccine vectors.

Details

Ressource 1Download: BIB_E7534DDC83F4.P001.pdf (1118.32 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_E7534DDC83F4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Improved NYVAC-based vaccine vectors.
Journal
Plos One
Author(s)
Kibler K.V., Gomez C.E., Perdiguero B., Wong S., Huynh T., Holechek S., Arndt W., Jimenez V., Gonzalez-Sanz R., Denzler K., Haddad E.K., Wagner R., Sékaly R.P., Tartaglia J., Pantaleo G., Jacobs B.L., Esteban M.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2011
Volume
6
Number
11
Pages
e25674
Language
english
Abstract
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine combination of a poxvirus and protein are needed. With this aim, in this investigation we have generated derivatives of the candidate vaccinia virus vaccine vector NYVAC with potentially improved functions. This has been achieved by the re-incorporation into the virus genome of two host range genes, K1L and C7L, in conjunction with the removal of the immunomodulatory viral molecule B19, an antagonist of type I interferon action. These novel virus vectors, referred to as NYVAC-C-KC and NYVAC-C-KC-ΔB19R, have acquired relevant biological characteristics, giving higher levels of antigen expression in infected cells, replication-competency in human keratinocytes and dermal fibroblasts, activation of selective host cell signal transduction pathways, and limited virus spread in tissues. Importantly, these replication-competent viruses have been demonstrated to maintain a highly attenuated phenotype.
Pubmed
Web of science
Open Access
Yes
Create date
17/02/2012 10:50
Last modification date
20/08/2019 16:10
Usage data